



कुमार साहब स्व. श्री दिलीप सिंह जुदेव जी
शासकीय सुपरस्पेशियलिटी हॉस्पिटल, कोनी, बिलासपुर (छ.ग.) 495009

टेलीफोन : 07752-289800, 299809 ईमेल - sshcimsbilaspur@gmail.com

क्रमांक / 2500 / क्रय / सुस्पे.हॉ. / 2026

बिलासपुर दिनांक : 27/08/2026

दावा - आपत्ति सूचना

विषय: उपकरण Continues Renal Replacement Therapy (Make- Gambro Dasco S.P.A. Baxter Model No- Prisma Flex 8.2) में होने वाले रिएजेंट/कन्ज्यूमेंबल/कंट्रोलर के क्रय के संबंध में।

—000—


उपकरणों में उपयोग होने वाले रिएजेंट्स/कन्ज्यूमेंबल/कंट्रोलर को क्रय छत्तीसगढ़ शासन, वाणिज्य एवं उद्योग विभाग, मंत्रालय, महानदी भवन, नवा रायपुर, अटल नगर की अधिसूचना क्रमांक एफ 20-70/2004 / 11/06, दिनांक 26.07.2023 के अंतर्गत छत्तीसगढ़ शासन भंडार क्रय नियम-2002 (तथा संशोधित 2022) के एकल निविदा में उल्लेखित उपनियम 4.3.1 के तहत उक्त सामग्री को बनाने वाली एकल निर्माता अथवा अधिकृत डीस्ट्रीब्यूटर से सीधे क्रय किया जाना प्रस्तावित है।

कुमार साहब स्व० श्री दिलीप सिंह जुदेव जी शासकीय सुपर स्पेशियलिटी हॉस्पिटल, कोनी, बिलासपुर, छ०ग० के नेफ्रोलॉजी विभाग द्वारा Continues Renal Replacement Therapy (Make- Gambro Dasco S.P.A. Baxter Model No- Prisma Flex 8.2) के उपकरणों में उपयोग होने वाले रिएजेंट्स/कन्ज्यूमेंबल/कंट्रोलर के निर्माता कंपनी मेसर्स Baxter (India) Pvt. Ltd. 5th Floor, Tower A, Building No. 9, DLF Cyber City, DLF Phase-III, Gurgaon-122002 के अधिकृत विक्रेता M/S GKS Healthsol LLP, B1/03, Palm Grove Villa, Ardee City, Sector 52, Gurgaon, Haryana-122003 से क्रय किया जाना प्रस्तावित है, उपयोगकर्ता विभाग द्वारा जारी किए गये स्वामित्व प्रमाण पत्र के आधार पर सभी की आम जानकारी वास्ते, संबंधित दस्तावेज अपलोड किए गये हैं।

उपरोक्त प्रक्रिया के किसी भी अंश से यदि, किसी को आपत्ति हो तो, वे इस दावा आपत्ति सूचना जारी होने के दिनांक 30 दिवस के भीतर (दिनांक 26.09.2026 समय 5.30 pm बजे तक) अपना दावा आपत्ति लिखित में आवेदन कुमार साहब स्व० श्री दिलीप सिंह जुदेव जी शासकीय सुपर स्पेशियलिटी हॉस्पिटल, कोनी, बिलासपुर, छ०ग०, पिन कोड-495009 के पते पर डाक/कोरियर के माध्यम से भेज सकते हैं। निर्धारित दिनांक एवं समय के पश्चात् प्राप्त दावा आपत्ति पर विचार नहीं किया जावेगा।

संलग्न- 01. उपयोगकर्ता विभाग से प्राप्त स्वामित्व प्रमाण पत्र एवं सामग्री का विवरण।

02. अन्य दस्तावेज।


संचालक प्राध्यापक एवं चिकित्सा अधीक्षक
कुमार साहब स्व० श्री दिलीप सिंह जुदेव जी
शासकीय सुपर स्पेशियलिटी हॉस्पिटल,
बिलासपुर, छ०ग०

List of Consumables of Prismaflex 6.xx

Sr. No	Description	MRP IN RS.	Tax GST
1	PRISMAFLEX M 60 SET	17,500	12%
2	PRISMAFLEX M100 SET	18,000	12%
3	PRISMAFLEX HF20 SET	21,500	12%
4	PRISMAFLEX TPE2000 Set	22,000	12%
5	Oxiris Set	70,000	12%
6	PRISMASOL BQ	2996	12%
7	REGIOCIT	3,450	12%
8	BIPHOSYL	3,450	12%
9	MARS KIT GAMBRO, TYPE 1116/1 -X-MARS	150000	12%

14-10-2022

SECTION – XIVMANUFACTURER'S AUTHORISATION FORM

To,

The CEO

HLL Infra Tech Services Limited

Procurement and Consultancy Division

B-14 A, Sector -62, Noida -201307, Uttar Pradesh.

Dear Sir,

Ref: Your TE document No. HITES/PCD/PMSSY-IV/25/Mix/2022-23 dated 12-08-2022

We, Baxter (India) Private Limited, who are proven and reputable importer Of Continuous Renal Replacement Therapy (CRRT) having factories at Gambro Dasco S.p.A, Via Modenese 66, Medolla (MO) 41036, Italy hereby authorise **M/s GKS Healthsol LLP, B1/03, Palm Grove Villa, Ardee City, Sector 52, Gurgaon, Haryana – 122003** to submit a tender, process the same further and enter into a contract with you against your requirement as contained in the above referred TE documents for the above goods manufactured by us.

We also state that we are not participating directly in this tender for the following reason(s):

*We are participating through **M/s GKS Healthsol LLP, who is our authorized distributor for the purpose of this tender.***

We further confirm that no supplier or firm or individual other than **M/s GKS Healthsol LLP, B1/03, Palm Grove Villa, Ardee City, Sector-52, Gurgaon, Haryana-122003** is authorized to submit a tender, process the same further and enter into a contract with you against your requirement as contained in the above-referred TE documents for the above goods manufactured by us.

We also hereby extend our full warranty, CMC as applicable as per clause 15 of the General Conditions of Contract, read with modification, if any, in the Special Conditions of Contract for the goods and services offered for supply by the above firm against this TE document.

We also hereby confirm that we would be responsible for the satisfactory execution of the contract placed on the authorized agent.

We also confirm that the price quoted by our agent shall not exceed the price which we would have quoted directly*

Thanking you and assuring you of our best services always

Yours Sincerely

For Baxter (India) Pvt. Ltd



Rahul Gupta
Manager Institutional Sales- Bax Solutions
Mobile: 9810592367
Email: rahul_gupta@baxter.com

Baxter (India) Pvt. Ltd.

CIN: U11312HR1999PTC038528

Registered Office: 5th Floor, Tower A, Building No. 8, DLF Cyber City, DLF Phase - III, Gurgaon - 122002, Haryana, India

Certificate No: G012019C155

Stamp Duty Paid: ₹ 101

GRN No: 44058414

Pen. Stamp:

Penalty: ₹ 0

Rev. Stamp Duty:

Deponent

Name: Gks Healthsol Llp

No/Floor: B1/03

Sector/Ward: 52

Landmark: Palm grove villa

City/Village: Ardee city

District: Gurgaon

State: Haryana

Phone: 9958763657

Purpose: LLP AGREEMENT to be submitted at Concerned office

The authenticity of this document can be verified by scanning this QR Code through smart phone or on the website <https://regashry.hic.in>

FIRST SUPPLEMENTARY LLP AGREEMENT OF GKS HEALTHSOL LLP (hereinafter FSELLP Agreement)

LLPIN- AAO-0901

(As per The Limited Liability Partnership Act, 2008, hereinafter called the Act)

THIS AGREEMENT made at Gurugram on this 09th day of March, 2019.

BY AND BETWEEN:

1. **Sh. Gagan Kumar Khosla**, Son of Lt. Sh. Naresh Khosla, residing at House No B-1/03 Palm Grove Villas, Ardee City, Sector-52, Gurgaon, Haryana-122003, hereinafter referred to as the **FIRST PARTY**
2. **Sh. Anuj**, S/o Sh. Raj Padam, residing at M 12, Third Floor, Kailash Colony, Delhi-110048 herein referred to as **SECOND PARTY**
3. **Smt. Madhu Gautam**, D/o Smt. Ram Lakhan Tripathi, residing at 47 Columbia St. Dominic Road, Opp St. Andrews College, Mumbai-400050 herein referred to as **THIRD PARTY**

GKS HEALTHSOL LLP

Designated Partner

GKS HEALTHSOL LLP

Designated Partner

GKS HEALTHSOL LLP

Designated Partner

Mr. Gagan Kumar Khosla,
DIN- 01442325
S/O Sh. Naresh Khosla,
House No B-1/03 Palm Grove Villas
Ardee City, Sector-52, Gurgaon, Haryana-122003
GKS HEALTHSOL LLP

Gagan Khosla
Designated Partner

Mr. Anuj, DIN- 08060222
S/O Sh. Raj Padam,
M 12, Third Floor,
Kailash Colony, Delhi-110048
GKS HEALTHSOL LLP

Anuj
Designated Partner

Ms. Madhu Gautam, DIN: 08337739
D/o Sh. Ram Lakhan Tripathi
47 Columbia St. Dominic Road,
Opp St. Andrews College, Mumbai-400050

GKS HEALTHSOL LLP

Madhu Gautam
Designated Partner

WITNESS (First Party)

Ritu Singh
Name: Ritu Singh
S/D/W/o Sh. Pardeep Singh
Address: Flat- 505, Park Royal Society
Gilt-Sa, Sec 52, Gurgaon

WITNESS (Second Party)

Gagan Kumar
Name: Gagan Kumar
S/D/W/o Anuj
Address: 66B/21, Street No-10, Shringi Park
Gurgaon-122001

WITNESS (Third Party)

Mirakshi
Name: Mirakshi
S/D/W/o Sh. Y.L. Kalia
Address: 47A, Jawahar Colony
Faidabad



Parveen Kumar Arora
Parveen Kumar Arora
Advocate & Notary
Sub Tehsil Wazirabad, Sec-58
Gurgaon (Haryana)

09 MAR 2019



GOVERNMENT OF INDIA
MINISTRY OF CORPORATE AFFAIRS
Central Registration Centre

Form 16

[Refer Rule 11(3) of the Limited Liability Partnership Rules, 2009]
CERTIFICATION OF INCORPORATION

LLP Identification Number: **AAO-0901**

It is hereby certified that GKS HEALTHSOL LLP is incorporated pursuant to section 12(1) of the Limited Liability Partnership Act, 2008.

Given under my hand at Manesar this Twenty first day of January Two thousand nineteen.



Wagh Tushar Mohan

For and on behalf of the Jurisdictional Registrar of Companies
Registrar of Companies
Central Registration Centre

Disclaimer: This certificate only evidences incorporation of the LLP on the basis of documents and declarations of the applicant(s). This certificate is neither a license nor permission to conduct business or solicit deposits or funds from public. Permission of sector regulator is necessary wherever required. Registration status and other details of the LLP can be verified on www.mca.gov.in

Mailing Address as per record available in Registrar Office:

GKS HEALTHSOL LLP

House No B-1/03 Palm Grove Villas,,Ardee City, Sector-52,Gurgaon,Gurgaon,Haryana,122011,India



Dated: 19-09-2025

To,
The Principal
Chhattisgarh Institute of Medical Sciences (CIMS)
Bilaspur

**Ref: NOA : HITES/PCD/PMSSY-IV/25/Mix/2023-24/3388 Dated
2/12/2023**

**Sub: Authority letter for supply of consumables of CRRT machine
supplied against above mentioned NOA**

Dear Sir/Madam,

We are pleased to inform you that M/s GMS Healthsol LLP, B1/03, Palm Grove Villa, Ardee City, Sector 52, Gurgaon, Haryana - 122003, is our Authorized Distributor for your institution. They are authorized to collect orders, raise invoices, affect supplies and collect payments thereof.

Purchase orders may be issued in their favour with intimation to us on id mentioned below.

This authority letter is valid till 31st Mar, 2026

Yours truly,

For Vantive Healthcare Private Limited



Ajay Singh Chambyal
Manager - Institutional Sales
Mobile: 8826103999
Email: ajay.singh.chambyal@vantive.com

CERTIFIED TRUE COPY OF THE RESOLUTION PASSED AT THE MEETING OF THE BOARD OF DIRECTORS OF BAXTER INDIA PRIVATE LIMITED HELD ON THURSDAY, 19th DECEMBER 2024 AT 04.00 P.M AT REGISTERED OFFICE OF THE COMPANY SITUATED AT 5TH FLOOR, TOWER A, BUILDING NO 9, DLF CYBER CITY, DLF PHASE – III, GURGAON – 122002, HARYANA, INDIA.

Take note of Spin off Renal Business

Board took note that pursuant to the intent of Baxter International Inc. (ultimate parent company) announced on 6th January 2023 to separate the renal care and acute therapy business in all its subsidiaries, the renal and acute therapy business of Baxter India Private Limited will be transferred to Vantive Healthcare Private Limited to implement the Global Separation decision. After discussion it was:

RESOLVED THAT The Board takes note of the spin-off activities undertaken by the Company, as presented to the Board.

FURTHER IT IS RESOLVED THAT any Director or the Company Secretary of the Company be and are hereby authorized to sign any documents, agreements, or instruments on behalf of the Company, as may be required in connection with the said spin-off activities.

RESOLVED FURTHER THAT a copy of this Resolution is filed with the relevant authorities, as may be required under applicable laws.

**Certified true copy
For Baxter India Private Limited**

DEEPAI (Digitally signed by
DEEPAI KAKKAR
Date: 2024.12.19 08:
18:00:57 +05'30')
KAKKAR

Deepali Kakkar
Company Secretary
M. No. A47539
Faridabad-121002

CERTIFIED TRUE COPY OF THE RESOLUTION PASSED AT THE BOARD MEETING OF VANTIVE HEALTHCARE PRIVATE LIMITED HELD ON MONDAY, 2ND DECEMBER 2024 AT 04.30 P.M. AT 5TH FLOOR, TOWER A, BLDG 9, DLF CYBER CITY PHASE III, DLF QE GURGAON-122002, HARYANA, INDIA.

Authorisation to approve the Transactions.

The Board is informed that Baxter International Inc. of which the Company is an indirect wholly owned subsidiary, on 6 January 2023, announced its intent to separate its renal care and acute therapies businesses (the "Vantive Business"), creating a new publicly traded company (generally, such separation, the "Global Separation"). The Global Separation of the Vantive Business will result in the creation of Vantive Health Inc. ("Vantive"), a new publicly traded company, and the following key goals are expected to be achieved with its implementation:

- (i) enhance management focus with respect to each business, increasing operational flexibility and allowing each company to capitalize on growth opportunities in its respective markets,
- (ii) increase the aggregate equity value of Baxter and Vantive,
- (iii) increase the effectiveness of stock-based incentive compensation by providing management and employees with incentives that more directly align with the operating and financial performances of the business in which they participate, enhancing the ability of each company to attract, retain, and incentivize qualified personnel,
- (iv) provide each company with its own distinct equity that relates solely to its business to use in pursuing strategic opportunities, and
- (v) allow each company to tailor its capital structures and capital return policies based on its particular business and financial needs, providing flexibility to better manage capital structure based on each company's forecasted cash generation, planned investments, credit rating requirements, acquisition activity, capital returns, among other factors. It is contemplated that the Global Separation will be implemented pursuant to one or more transactions. In this regard, the Company is requested to authorize, approve and ratify (i) the Global Separation, (ii) the Transactions and (iii) the execution and delivery of the Separation Documents (as defined in the resolution below), and the performance of any related formalities.

The Board is requested to consider the same and if thought fit, to pass the following resolution unanimously:

WHEREAS, the Company is an indirect wholly owned subsidiary of Baxter International Inc., a Delaware corporation, ("Baxter");

WHEREAS, on 6 January 2023, Baxter announced its intent to separate its renal care and acute therapies businesses (the "Vantive Business"), creating a new publicly traded company (generally, such separation, the "Global Separation");

WHEREAS, Baxter is undertaking a series of internal transactions in order to facilitate the Global Separation;

Vantive Healthcare Private Limited

CIN: U44700HR2024PTC117889

Registered Office: 5th Floor, Tower A Bldg 9, DLF Cyber City Phase III, Gurgaon-122002, Haryana, India

T: 01244500100 E: baxterindia@baxter.com W: www.baxter.in



WHEREAS, the Global Separation of the Vantive Business will result in the creation of Vantive Health Inc. ("Vantive"), a new publicly traded company, and the following key goals are expected to be achieved with its implementation: (i) enhance management focus with respect to each business, increasing operational flexibility and allowing each company to capitalize on growth opportunities in its respective markets, (ii) increase the aggregate equity value of Baxter and Vantive, (iii) increase the effectiveness of stock-based incentive compensation by providing management and employees with incentives that more directly align with the operating and financial performances of the business in which they participate, enhancing the ability of each company to attract, retain, and incentivize qualified personnel, (iv) provide each company with its own distinct equity that relates solely to its business to use in pursuing strategic opportunities, and (v) allow each company to tailor its capital structures and capital return policies based on its particular business and financial needs, providing flexibility to better manage capital structure based on each company's forecasted cash generation, planned investments, credit rating requirements, acquisition activity, capital returns, among other factors;

WHEREAS, it is contemplated that the Global Separation will be implemented pursuant to one or more transactions including, without limitation, those described in Schedule A of these resolutions, the particulars of which have been carefully reviewed and considered by the directors of the Company to their satisfaction (the "Transactions");

WHEREAS, in order to consummate the Transactions, the Board deems it to be in the best interests of the Company to enter into one or more agreements, instruments or ancillary documents relating to the Transactions (the "Transaction Documents"), as applicable, including, without limitation, those listed in Schedule A of this resolution, the particulars of which have been reviewed and considered by the directors of the Company to their satisfaction;

WHEREAS, in addition to the Transaction Documents, the Company may enter into additional agreements, instruments or other documents, including without limitation, memoranda of delivery and acceptance, one or more manufacturing agreements, supply agreements, transition services agreements, interim operating model agreements, contribution agreements, payment direction agreements, assignment and assumption agreements, leases, quality agreements, agreements related to the processing and/or transfer of personal data, licenses and/or sublicenses which are in the judgment of the Authorized Representatives (as defined below), necessary or appropriate to consummate the Global Separation (the "Separation Agreements" and, collectively with the Transaction Documents, the "Separation Documents"); and

WHEREAS, the undersigned deem it in the best interests of the Company to authorize, approve and ratify (i) the Global Separation, (ii) the Transactions and (iii) the execution and delivery of the Separation Documents.

NOW, THEREFORE, BE IT RESOLVED, that the Global Separation, the Transactions, and any and all related closing and post-closing formalities to be performed by the Company in connection with the Transactions, as well as the form, terms and conditions of the Separation Documents and any additional agreement or arrangement ancillary to the Global Separation, and all of the transactions contemplated thereby, with such changes as the Authorized Representatives (as defined below) or their designees deem

Vantive Healthcare Private Limited

CIN: U44700MH2024PTC117989

Registered Office: 5th Floor, Tower-A Bldg 9, DLF Cyber City Phase-II, Gurgaon-122002, Haryana, India
T: 8134608276 E: baxterindia@baxter.com W: www.baxter.in



necessary and in the best interests of the Company be, and hereby have been reviewed and considered by the Board to its satisfaction, and are hereby unanimously approved, ratified and authorized in all respects.

For Vantive Healthcare Private Limited


.....
Vikas Taneja

Director

DIN: 10459435

Add: 58, Kewal Park,
Guru Nanak Marg, Azadpur,
Delhi - 110033




.....
Angita Singh

Director

DIN: 10459436

Add: F-1803, Microtek Greenburg, St Xaviers
High School, Sector 86, Nakhrola, Gurgaon-
122004, Haryana, India

Vantive Healthcare Private Limited

CIN: U46497HR2020PTC117800

Registered Office: 5th Floor, Tower-A Bldg 8, DLF Cyber City Phase-III, Gurgaon-122002, Haryana, India

T: 01244080296 E: secretary@vantive.com W: www.vantive.in